Biocryst Pharmaceuticals reported $40.38M in Gross Profit on Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Adamas Pharmaceuticals ADMS:US 25.32M 3.88M
Alexion Pharmaceuticals ALXN:US $ 1511.1M 71.5M
Alnylam Pharmaceuticals ALNY:US $ 154.97M 35.33M
Biocryst Pharmaceuticals BCRX:US $ 40.38M 9.24M
Chugai Pharma 4519:JP Y 183070M 29718M
Daiichi Sankyo 4568:JP Y 178489M 428M
Gilead Sciences GILD:US $ 6198M 1371M
GlaxoSmithKline GSK:LN 6.26B 682M
Glaxosmithkline GSK:US $ 6255M 682M
Intra Cellular Therapies ITCI:US $ 20.21M 2.2M
IONIS PHARMACEUT IONS:US $ 130M 7.21M
Karyopharm Therapeutics KPTI:US $ 37.1M 15.64M
Neurocrine Biosciences NBIX:US $ 291.8M 6M
Ptc Therapeutics PTCT:US $ 132.2M 22.89M
Regeneron Pharmaceuticals REGN:US $ 2999.6M 1445.2M
Sarepta Therapeutics SRPT:US $ 165.96M 21.39M
Ultragenyx Pharmaceutical RARE:US $ 77.47M 6.37M
Vertex Pharmaceuticals VRTX:US $ 1747.65M 182.25M
YTE INCY:US $ 778.52M 105.44M
Zogenix ZGNX:US $ 21.32M 3.75M